Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
4.650
+0.330 (7.64%)
Mar 9, 2026, 1:36 PM EDT - Market open
Neuphoria Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Mar '26 Mar 9, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| Market Capitalization | 25 | 13 | - | - | - | - | |
| Enterprise Value | 2 | -4 | - | - | - | - | |
| Last Close Price | 4.32 | 7.10 | - | - | - | - | |
| PS Ratio | 1.62 | 0.85 | - | - | - | - | |
| PB Ratio | 0.78 | 0.70 | - | - | - | - | |
| P/TBV Ratio | 1.47 | 2.40 | - | - | - | - | |
| P/FCF Ratio | - | 172.83 | - | - | - | - | |
| P/OCF Ratio | - | 172.83 | - | - | - | - | |
| Debt / Equity Ratio | 0.00 | 0.01 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Debt / FCF Ratio | - | 1.93 | - | - | - | - | |
| Net Debt / Equity Ratio | -0.74 | -0.74 | -0.70 | -0.53 | -0.58 | -0.58 | |
| Net Debt / EBITDA Ratio | 18.45 | 84.56 | 0.72 | 0.56 | 1.97 | 2.96 | |
| Net Debt / FCF Ratio | 9.37 | -182.08 | 0.84 | 0.80 | 1.51 | 3.67 | |
| Asset Turnover | 0.55 | 0.56 | - | - | 0.10 | 0.02 | |
| Quick Ratio | 8.76 | 3.37 | 3.33 | 4.58 | 12.02 | 12.55 | |
| Current Ratio | 9.04 | 3.56 | 3.45 | 4.87 | 12.46 | 13.10 | |
| Return on Equity (ROE) | -26.07% | -2.03% | -78.44% | -71.40% | -41.64% | -28.86% | |
| Return on Assets (ROA) | -4.25% | -1.84% | -39.58% | -37.41% | -18.40% | -14.48% | |
| Return on Capital Employed (ROCE) | -5.50% | -3.40% | -74.70% | -83.50% | -28.40% | -19.80% | |
| Earnings Yield | -23.35% | -2.77% | - | - | - | - | |
| FCF Yield | -9.74% | 0.58% | - | - | - | - | |
| Buyback Yield / Dilution | -123.33% | -95.01% | 99.94% | -8.53% | -73.52% | -43.14% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.